ArticleFrontiers in immunology2026
The epidemiological trends of multiple sclerosis among women of child-bearing age: a global analysis from 1990 to 2021 and forecasts to 2040.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multiple sclerosis (MS) shows marked female predominance, particularly among women of childbearing age (WCBA, 15-49 years), yet their specific disease burden remains under characterized. Using Global Burden of Disease (GBD) 1990-2021 data, we conducted the first comprehensive analysis of MS trends in WCBA globally, with projections to 2040, to guide targeted interventions for this vulnerable population. Methods: We analyzed age-standardized incidence (ASIR), prevalence (ASPR), mortality (ASMR), and disability-adjusted life years (ASDR) rates across 204 countries using GBD 2021 data. Our analytical approach incorporated Pearson correlation to examine Socio-demographic Index (SDI) relationships, decomposition analysis to identify burden drivers, and frontier analysis to assess disease control efficiency gaps. We employed Bayesian Age-Period-Cohort modeling alongside ARIMA for 20-year projections, with joinpoint regression analyzing temporal trends through annual percentage changes. Age-period-cohort effects were further disentangled through APC modeling, with stratification by age group, SDI level, and geographic region. Results: Between 1990-2021, WCBA experienced a 48% rise in MS incidence and 66% increase in prevalence, with mortality growing by 17% despite a 7% DALYs reduction. Age-standardized rates improved (ASMR:-0.35; ASDR:-0.3), though burden varied regionally: Australasia showed greatest incidence growth versus East Asia's decline, while Central Latin America led prevalence increases. High-SDI countries (>0.4) carried disproportionate burden, peaking at ages 45-49 (incidence:30-34 years). Projections indicate rising crude rates but falling ASDR. Low-SDI nations (e.g., Cambodia) demonstrated optimal control versus high-SDI underperformers (e.g., Sweden). Birth cohorts revealed generally declining risk (RR1.146→0.805) except 2002-2006(RR1.413), with elevated DALYs(20-25y) and prevalence(30-35y) warranting targeted action. Discussion: This study reveals key disparities in MS burden among WCBA, with high-SDI countries showing paradoxical high burden yet improvement potential. The 2002-2006 cohort rebound and persistent burdens in 30-49-year-olds highlight critical intervention windows. While low-SDI countries demonstrate unexpected control efficiency, rising crude rates globally underscore the growing women's health challenge of MS, particularly given projected prevalence increases. These findings advocate for tailored, age-specific management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.